Halozyme Q2 Revenue Surges 48% to $481M; Royalties Up 50%; $1B Buyback Authorized
HALO sits 47% above its 52-week low of $61.225.
Summary
Record Q2 2026 revenue of $481M (+48% YoY) and royalty revenue of $308M (+50%) were driven by DARZALEX SC, VYVGART Hytrulo, and Phesgo. A new $1B buyback was authorized, and multiple new collaborations were signed.
Key Events · Earnings and Guidance · HALO
-
Record Q2 Revenue and Earnings
Total revenue of $481M, up 48% YoY; royalty revenue of $307.7M, up 50% YoY. Net income of $229.9M, diluted EPS of $1.90.
-
Royalty Growth Driven by Key Products
DARZALEX SC royalties of $152.2M (+27%), VYVGART Hytrulo royalties of $72.6M (+143%), and Phesgo royalties of $28.4M (+8%).
-
$1B Share Repurchase Authorization
Board authorized a new $1B buyback program in May 2026; $332.7M repurchased in Q2 at an average price of $69.30 per share.
-
Multiple New Collaborations Signed
New ENHANZE deals with GSK (oncology, including ADCs), Incyte (INCA033989), and an undisclosed partner (nucleic acid therapeutic). New Hypercon deals with Vertex and Oruka.
Analysis · HALO · Life Sciences
A blowout quarter saw total revenue jump 48% to $481 million, while royalty revenue climbed 50% to $308 million—both records. The surge was fueled by blockbuster ENHANZE-partnered products DARZALEX SC, VYVGART Hytrulo, and Phesgo. Net income reached $230 million, or $1.90 per diluted share. The company also authorized a new $1 billion share repurchase program and bought back $333 million in stock during the quarter. Multiple new collaborations—including with GSK, Incyte, Vertex, and Oruka—expand the ENHANZE and Hypercon pipelines. Positive clinical and regulatory updates across the partnered portfolio reinforce the long-term royalty growth story. The only cautionary note is a risk factor highlighting potential IRA drug price negotiation impacts on combination therapies, though no immediate financial effect is indicated.
At the time of this filing, HALO was trading at $90.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10.2B. The 52-week trading range was $61.23 to $86.00. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.